What is the most appropriate management for two TI‑RADS 4 thyroid nodules after ultrasound?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Two TR-4 Thyroid Nodules

For two TR-4 thyroid nodules, determine if they meet size criteria for fine-needle aspiration (FNA): biopsy both nodules if they are ≥1.5 cm, or initiate ultrasound surveillance at 1,2,3, and 5 years if they are smaller. 1

Size-Based Decision Algorithm

The ACR TI-RADS guideline establishes clear size thresholds that drive management:

  • If both nodules are ≥1.5 cm: Proceed with FNA of both nodules. The ACR TI-RADS committee specifically recommends targeting no more than two nodules with the highest point totals that meet FNA criteria, which aligns perfectly with your scenario of two TR-4 nodules 1

  • If nodules are <1.5 cm: Initiate surveillance ultrasound protocol rather than immediate biopsy

Surveillance Protocol for Sub-Threshold Nodules

For TR-4 nodules below the 1.5 cm FNA threshold, follow this specific timeline:

  • Year 1: First follow-up ultrasound
  • Year 2: Second follow-up ultrasound
  • Year 3: Third follow-up ultrasound
  • Year 5: Final follow-up ultrasound 1

Stop surveillance at 5 years if no growth occurs, as stability over this timeframe reliably indicates benign behavior 1

Important Caveat on Small Nodules

Recent evidence suggests that TR-4 nodules below size thresholds still carry meaningful malignancy risk (20% in one study) 2. However, the established guideline framework prioritizes the 1.5 cm threshold to balance detection of clinically significant cancers against overdiagnosis of indolent disease 1.

What Constitutes Significant Growth

If nodules grow during surveillance, apply these specific criteria:

  • 20% increase in at least two dimensions AND minimum 2 mm absolute increase, OR
  • 50% or greater increase in volume 1

Critical point: Compare current measurements to the earliest available scan, not just the immediately preceding one, as growth may not be apparent with sequential-only comparison 1

If a nodule grows significantly but remains below 1.5 cm at 5 years, continued surveillance is warranted despite lack of published evidence for this scenario 1

Documentation Requirements

For proper tracking of your two nodules:

  • Number each nodule sequentially (Nodule #1, Nodule #2)
  • Document precise location (right/left lobe, upper/mid/lower pole, and if needed: anterior/posterior/medial/lateral)
  • Measure in three axes: maximum axial dimension, perpendicular axial dimension, and maximum longitudinal dimension 1
  • Include the nodule's halo in measurements if present 1

This meticulous documentation becomes essential when multiple nodules exist, preventing confusion on subsequent scans.

Why Not Biopsy Everything?

The guideline explicitly states that biopsying three or more nodules is poorly tolerated by patients, increases cost with little benefit, and adds risk 1. With two TR-4 nodules, you're at the recommended maximum for biopsy—but only if they meet the size threshold.

Size should not be the primary criterion—the ACR discourages using "dominant nodule" terminology for the largest lesion, as architecture (reflected in the TR score) takes precedence 1

Malignancy Context

TR-4 nodules carry moderate suspicion. Research shows that among nodules below biopsy thresholds that were biopsied anyway, TR-4 nodules had a 17.7% malignancy rate 3, while another study found 20% malignancy in TR-4 nodules <10 mm 2. However, these studies examined selected populations that underwent biopsy despite not meeting criteria, introducing selection bias. The guideline's size thresholds are designed to capture clinically significant cancers while avoiding overtreatment of indolent microcarcinomas 1.

References

Research

Follow up or FNAB?: Malignancy Rates of ACR TI-RADS 4 and 5 Thyroid Nodules <10 mm in Diameter.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.